DiaMedica Therapeutics (DMAC) Net Cash Flow (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Net Cash Flow for 9 consecutive years, with $275000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow fell 81.91% year-over-year to $275000.0; the trailing twelve-month figure through Jun 2026 stood at $978000.0 (up 109.82% YoY), and the FY2025 full-year result was $12.6 million, up 928.99% from the prior year.
• Net Cash Flow improved to $275000.0 in Q2 2026 per DMAC's latest filing, from -$10.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $12.3 million in Q4 2025 and bottomed at -$10.8 million in Q1 2026.
• Historically, Net Cash Flow has averaged $21111.1 across 5 years, with a median of -$363500.0 in 2022.
• The sharpest annual moves came in 2023 and 2026: Net Cash Flow surged 12206.67% in 2023, then plunged 2376.38% in 2026.
• Over 5 years, Net Cash Flow stood at $2.0 million in 2022, then grew by 18.09% to $2.3 million in 2023, then tumbled by 147.99% to -$1.1 million in 2024, then soared by 1207.84% to $12.3 million in 2025, then slumped by 97.76% to $275000.0 in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $275000.0, -$10.8 million, and $12.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.